U.S. employers are limiting or eliminating insurance coverage for GLP-1 weight-loss drugs like Novo Nordisk's Wegovy. Surging medication prices have created significant financial strain on corporate health plans. Many large employers report that spending on these drugs far exceeded initial projections.
Companies are tightening eligibility by mandating lifestyle modification programs or removing obesity treatment coverage entirely. A benefits consulting firm reports that 11% of large employers have already dropped or plan to drop coverage. These restrictions create hurdles for patient access and may slow sales growth for manufacturers like Novo Nordisk.